• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Analysis of AstraZeneca

  • ID: 569373
  • November 2013
  • 100 Pages
  • Aruvian's R'search
Special Offer Banner
Offer ends 31st Jul 2015


  • AstraZeneca
  • GlaxoSmithKline
  • Novartis
  • SanofiSA
  • MORE

AstraZeneca is the second largest pharmaceutical company in the UK. The company was formed in 1999 by the merger of Swedish-based Astra and UK-based Zeneca Group. AstraZeneca has a strong presence in the US and retains a significant presence in Sweden as a legacy of Astra.

The UK pharmaceutical industry is among the world’s leading manufacturer and exporter of medicines. With the combination of a strong history and favorable environment, the UK pharmaceutical industry has been able to perform better than its potential, despite difficulties faced by the industry throughout the UK and Europe. This growth can be partly attributed to innovative products launched as well as continued promotion of the sector to retain brand recognition.

AstraZeneca has 27 manufacturing sites in 19 countries. The company’s portfolio of marketed medicines include Arimidex, Crestor, Nexium, Seroquel, Symbicort, Pulmicort, Zoladex, Seloken/Toprol-XL, Diprivan and Merrem. On January 31, 2007, AstraZeneca announced its acquisition of Arrow Therapeutics Ltd., a biotechnology company focused on the discovery and development of anti-viral therapies.

This R’search presents Analysis READ MORE >

Note: Product cover images may vary from those shown


  • AstraZeneca
  • GlaxoSmithKline
  • Novartis
  • SanofiSA
  • MORE

A. Executive Summary

B. Looking at the Industry
B.1 Industry Definition
B.2 Brief Profile of the Industry
B.3 Impacts on the Industry
B.4 Challenges Facing the Industry
B.5 Future Perspective

C. Industry PEST Framework Analysis
C.1 Political Aspects
C.2 Economic Aspects
C.3 Social Aspects
C.4 Technological Aspects

D. Looking at AstraZeneca
D.1 Company Profile
D.2 History of the Company
D.3 Ownership Pattern in the Company
D.4 Organizational Divisions
D.5 Profiling the Key Executives
D.6 Products & Services

E. Looking at Business
E.1 Business Segments
E.2 Geographical Segments
E.3 Company Subsidiaries

F. AstraZeneca: SWOT Framework Analysis
F.1 Strengths to Build Upon
F.2 Weaknesses to Overcome
F.3 Opportunities to Exploit
F.4 Threats to Overcome

G. Profiling the Competition
G.1 GlaxoSmithKline
G.1.1 Corporate Profile
G.1.2 Business Segment Analysis
G.1.3 Financial Analysis
G.1.4 SWOT Analysis
G.2 Novartis AG
G.2.1 Corporate Profile
G.2.2 Business Segment Analysis
G.2.3 Financial Analysis
G.2.4 SWOT Analysis
G.3 Sanofi SA
G.3.1 Corporate Profile
G.3.2 Business Segment Analysis
G.3.3 Financial Analysis
G.3.4 SWOT Analysis

H. AstraZeneca: Financial Analysis
H.1 Current Financials
H.2 Balance Sheet
H.3 Profit & Loss Statement
H.4 Ratio Analysis
H.4.1 Growth Rates
H.4.2 Price Ratios
H.4.3 Profit Margins
H.4.4 Financial Condition
H.4.5 Investment Returns
H.4.6 Management Efficiency

I. AstraZeneca: Future Perspective

J. Appendix

K. Glossary of Terms

Note: Product cover images may vary from those shown




Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Grifols, S.A. Takeda Pharmaceutical Company Limited Alexion Pharmaceuticals Teva Pharmaceutical Industries Ltd. Endo International Plc. Essilor International S.A.